QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 on-october-20-2025-curis-received-nasdaq-notice-indicating-that-the-panel-has-granted-the-company-an-exception-until-november-14-2025t-o-regain-compliance-with-the-mvls-requirement

As previously disclosed, on August 21, 2025, Curis, Inc. (the "Company") received notice from the Listing Qualification...

 curis-q2-eps-068-beats-136-estimate-sales-275m-beat-264m-estimate

Curis (NASDAQ:CRIS) reported quarterly losses of $(0.68) per share which beat the analyst consensus estimate of $(1.36) by 50 p...

 a-peek-at-curiss-future-earnings
A Peek at Curis's Future Earnings
08/04/2025 21:04:09

 curis-announces-7m-registered-direct-offering-and-private-placement-selling-154m-shares-at-2275-each-the-combined-purchase-price-for-1-share-and-the-associated-common-warrant-is-2275-combined-purchase-price-for-1-pre-funded-warrant-and-the-associated-common-warrant-is-2265

Curis, Inc. ("Curis") (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an or...

 hc-wainwright--co-assumes-curis-at-buy-announces-price-target-of-17

HC Wainwright & Co. analyst Joseph Pantginis assumes Curis (NASDAQ:CRIS) with a Buy rating and announces Price Target of...

 earnings-outlook-for-curis
Earnings Outlook For Curis
05/05/2025 20:02:50

 hc-wainwright--co-maintains-buy-on-curis-lowers-price-target-to-16

HC Wainwright & Co. analyst Edward White maintains Curis (NASDAQ:CRIS) with a Buy and lowers the price target from $20 t...

 hc-wainwright--co-reiterates-buy-on-curis-maintains-20-price-target

HC Wainwright & Co. analyst Edward White reiterates Curis (NASDAQ:CRIS) with a Buy and maintains $20 price target.

 hc-wainwright--co-reiterates-buy-on-curis-maintains-20-price-target

HC Wainwright & Co. analyst Edward White reiterates Curis (NASDAQ:CRIS) with a Buy and maintains $20 price target.

 curis-q3-2024-gaap-eps-170-beats-183-estimate-cash-and-cash-equivalents-of-316m-is-expected-to-provide-cash-runway-into-mid-2025

Curis (NASDAQ:CRIS) reported quarterly losses of $(1.70) per share which beat the analyst consensus estimate of $(1.83) by 7.1 ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION